



# METHOD FOR EARLY TAKO-TSUBO CARDIOMIOPHATY PROGNOSIS IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE

#### The Need

Aneurysmal subarachnoid haemorrhage represents a serious medical emergency with high mortality and morbidity due to early rebleeding. Approximately 11% of these patients die before receiving medical attention and 40% die within 4 weeks after admission to hospital. Among survivors 30% have a considerable limitation for activities of daily living and often suffer from cardiac

complications associated with an increased risk of short-term death. Tako-Tsubo cardiomyopathy (TTC) is the main cardio-dysfunction that occurs after neurological damage The prevalence in SAH 's patients is between 20% and 30%, with a higher prevalence in women. There is a medical need in predicting risk of TTC in early SAH stages in order to adapt accordingly their treatment and monitoring.

#### **The Solution**

The technology provides an in vitro method able to predict, at day 0 with 100% efficiency, patients with a subarachnoid aneurysmal haemorrhage that will develop a complication of Tako-Tsubo cardiomyopathy and therefore should follow a preventive treatment and monitoring.

The solution is based in determining the combined level of two molecules or their mRNA in serum/ blood samples obtained from the patient at emergency arrival.

#### **Innovative Aspects**

- Early prediction of SAH complications into a TTC cardiomyopathy.
- Rapid and easy identification of patients.
- Preventive treatment and monitoring of these patients.
- Reduction of severity effects and mortality.
- Minimally invasive method from serum or blood samples
- The IVD can be easily implemented to be performed in health services' currently available devices

### Stage of Development:

The method is currently being validated by the group in a bigger cohort of patients arriving though emergency services at hospitals.

## **Intellectual Property:**

• Spanish patent filed (3<sup>rd</sup> March 2021)

## Aims

Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.



# **Contact details**

Centro de Investigación Biomédica en Red (CIBER) otc@ciberisciii.es transferencia@ciberisciii.es https://www.ciberisciii.es/en